全文获取类型
收费全文 | 16727篇 |
免费 | 3227篇 |
国内免费 | 294篇 |
专业分类
耳鼻咽喉 | 701篇 |
儿科学 | 380篇 |
妇产科学 | 322篇 |
基础医学 | 1043篇 |
口腔科学 | 412篇 |
临床医学 | 2127篇 |
内科学 | 4071篇 |
皮肤病学 | 649篇 |
神经病学 | 1652篇 |
特种医学 | 938篇 |
外科学 | 4246篇 |
综合类 | 95篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 975篇 |
眼科学 | 418篇 |
药学 | 445篇 |
中国医学 | 16篇 |
肿瘤学 | 1755篇 |
出版年
2024年 | 100篇 |
2023年 | 543篇 |
2022年 | 244篇 |
2021年 | 452篇 |
2020年 | 817篇 |
2019年 | 316篇 |
2018年 | 800篇 |
2017年 | 757篇 |
2016年 | 927篇 |
2015年 | 828篇 |
2014年 | 1122篇 |
2013年 | 1296篇 |
2012年 | 710篇 |
2011年 | 712篇 |
2010年 | 897篇 |
2009年 | 1080篇 |
2008年 | 719篇 |
2007年 | 616篇 |
2006年 | 742篇 |
2005年 | 608篇 |
2004年 | 493篇 |
2003年 | 441篇 |
2002年 | 433篇 |
2001年 | 260篇 |
2000年 | 176篇 |
1999年 | 253篇 |
1998年 | 326篇 |
1997年 | 323篇 |
1996年 | 375篇 |
1995年 | 341篇 |
1994年 | 226篇 |
1993年 | 183篇 |
1992年 | 189篇 |
1991年 | 191篇 |
1990年 | 117篇 |
1989年 | 166篇 |
1988年 | 123篇 |
1987年 | 107篇 |
1986年 | 121篇 |
1985年 | 121篇 |
1984年 | 108篇 |
1983年 | 90篇 |
1982年 | 101篇 |
1981年 | 74篇 |
1980年 | 69篇 |
1979年 | 54篇 |
1978年 | 63篇 |
1977年 | 56篇 |
1975年 | 55篇 |
1972年 | 39篇 |
排序方式: 共有10000条查询结果,搜索用时 515 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
5.
6.
7.
8.
9.
10.
Jun Agata Nobuyuki Ura Hideaki Yoshida Yasuyuki Shinshi Haruki Sasaki Masaya Hyakkoku Shinya Taniguchi Kazuaki Shimamoto 《Hypertension research》2006,29(11):865-874
Angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension. It is believed that treatment with an ARB increases the level of plasma angiotensin II (Ang II) because of a lack of negative feedback on renin activity. However, Ichikawa (Hypertens Res 2001; 24: 641-646) reported that long-term treatment of hypertensive patients with olmesartan resulted in a reduction in plasma Ang II level, though the mechanism was not determined. It has been reported that angiotensin 1-7 (Ang-(1-7)) potentiates the effect of bradykinin and acts as an angiotensin-converting enzyme (ACE) inhibitor. It is known that ACE2, which was discovered as a novel ACE-related carboxypeptidase in 2000, hydrolyzes Ang I to Ang-(1-9) and also Ang II to Ang-(1-7). It has recently been reported that olmesartan increases plasma Ang-(1-7) through an increase in ACE2 expression in rats with myocardial infarction. We hypothesized that over-expression of ACE2 may be related to a reduction in Ang II level and the cardioprotective effect of olmesartan. Administration of 0.5 mg/kg/day of olmesartan for 4 weeks to 12-week-old stroke-prone spontaneously hypertensive rats (SHRSP) significantly reduced blood pressure and left ventricular weight compared to those in SHRSP given a vehicle. Co-administration of olmesartan and (D-Ala7)-Ang-(1-7), a selective Ang-(1-7) antagonist, partially inhibited the effect of olmesartan on blood pressure and left ventricular weight. Interestingly, co-administration of (D-Ala7)-Ang-(1-7) with olmesartan significantly increased the plasma Ang II level (453.2+/-113.8 pg/ml) compared to olmesartan alone (144.9+/-27.0 pg/ml, p<0.05). Moreover, olmesartan significantly increased the cardiac ACE2 expression level compared to that in Wistar Kyoto rats and SHRSP treated with a vehicle. Olmesartan significantly improved cardiovascular remodeling and cardiac nitrite/ nitrate content, but co-administration of olmesartan and (D-Ala7)-Ang-(1-7) partially reversed this anti-remodeling effect and the increase in nitrite/nitrate. These findings suggest that olmesartan may exhibit an ACE inhibitory action in addition to an Ang II receptor blocking action, prevent an increase in Ang II level, and protect cardiovascular remodeling through an increase in cardiac nitric oxide production and endogenous Ang-(1-7) via over-expression of ACE2. 相似文献